ReviewAnnals of general psychiatry2021
Malondialdehyde concentrations in obsessive-compulsive disorder: a systematic review and meta-analysis.
Review in Annals of general psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- A Caudate Pathway-level Transcriptomic Signature of Translational, Bioenergetic, and Proteostatic Programs in Obsessive-compulsive Disorder.Journal of molecular neuroscience : MN · 2026Article
- Nutraceuticals and obsessive-compulsive disorder therapy.Advances in neurotoxicology · 2026Article
- Potential biomarkers and therapeutic targets for obsessive compulsive disorder: Evidences from clinical studies.Biochemia medica · 2024Review
- The Oxidative Status and NaBioMed research international · 2024Article
- The effect of major depressive disorder comorbidity on ischemia-modified albumin levels, a marker of oxidative stress, and antioxidant defense system in patients with obsessive compulsive disorder.Frontiers in psychiatry · 2024Article
- Investigation of the effects of oxidative stress, inflammation on the pathway of tryptophan/kynurenine in OCD.Acta neuropsychiatrica · 2023Article
- Untargeted metabolomics analysis in drug-naïve patients with severe obsessive-compulsive disorder.Frontiers in neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis aimed to investigate serum and plasma malondialdehyde (MDA) levels in patients with obsessive-compulsive disorder (OCD) in comparison to healthy controls.
methodsFollowing the PRISMA protocol, we searched for the relevant studies through the databases of Scopus, PubMed, Google Scholar, and web of science until September 2019 with no time restriction. Overall, nine studies were included in the current meta-analysis. Data were pooled using a random-effects model; in addition, standard mean difference (SMD) and/or weight mean difference (WMD) was calculated. Cochran's Q test and I-square (I
resultsOur systematic review included nine case-control studies (including 367 cases and 337 controls). Pooling findings from these studies showed a significantly higher MDA level in OCD patient compared to control groups (SMD = 1.62; 95% CI [0.53, 2.72]; I
conclusionWe found that MDA levels are higher in OCD patients than healthy controls. This finding highlights the importance of inflammatory responses in OCD patients that should be considered for future investigations. Further studies are recommended to expand current knowledge on this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.